Abstract
Psoriasis is an immune-mediated chronic inflammatory disease. Some studies have indicated that T helper type 17 (Th17) cell-related cytokines play a key role in the development of psoriasis. With further insight into the immunopathogenesis of psoriasis, new biological agents targeting the Th17 cell pathway, including interleukin (IL)-17 antagonists, IL-17 receptor antagonists, IL-23p19 antagonists and IL-12/23p40 antagonists, have brought new prospects for the treatment of psoriasis. Studies have shown that these new biological targeted drugs extert marked therapeutic effects, but they also have adverse effects. Thus, further studies are needed to evaluate the clinical efficacy, safety and tolerability of these targeted drugs, so as to offer a better guide to their rational administration in clinical practice. Key words: Psoriasis; Th17 cells; Molecular targeted therapy; Antibodies, monoclonal; Cytokines
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
